Friday, November 13, 2026

Fed, ECB, and Major Central Banks Halt Rate Cuts as Inflation Persists Above Targets

The Federal Reserve will hold interest rates at current levels for an extended period as inflation stays above 2%, joining the European Central Bank, Bank of Russia, and Brazil's central bank in pausing easing cycles this week. The coordinated stance marks a global shift from the rate-cutting trajectory anticipated earlier this year, with policymakers prioritizing inflation control over growth stimulus.

From our archive, published before source-traceability. How we work

Source Trace Score4 source documents4 with a live linkVerifiability: Strong
Fed, ECB, and Major Central Banks Halt Rate Cuts as Inflation Persists Above Targets
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

Four major central banks paused their easing cycles this week as persistent inflation forces a global rethink of monetary policy. The Federal Reserve, European Central Bank, Bank of Russia, and Brazil's central bank all held rates steady, abandoning the rate-cutting path expected at the start of the year.

Former Cleveland Fed President Loretta Mester said the Fed can maintain current rates for an extended period while inflation exceeds its 2% target. "The labor market has stabilized, and they need to keep policy a bit restrictive to help inflation move back down to 2%. It's a good time to wait," Mester stated.

The pause reflects shifting dynamics in major economies. U.S. labor market weakness stems from immigration restrictions and tariffs rather than monetary factors, according to Mester. "It's not as vibrant of a labor market as you'd like, but that's because of the policies that have been put onto this economy, not anything a Fed tool like the fed funds rate can address," she said.

Geopolitical risks complicate policy decisions worldwide. Brazil's monetary policy director Nilton David warned that the Iran conflict "adds new layer of risk to Brazil's economic outlook and could argue for reassessment of how bank calibrates monetary policy after March meeting."

Mester emphasized the Fed's patience approach: "The Fed is in a very good position to hold for a while and see how the economy actually evolves." Policymakers require clear evidence of inflation returning to 2% or significant labor market deterioration before resuming cuts.

The divergence in views among Fed officials reflects current uncertainty. "In an environment this difficult to read, I don't think it's very unusual or surprising that you'd have different views. If everyone agreed, I'd be worried they're not working at things as robustly as they should," Mester said.

Financial markets face prolonged higher borrowing costs across major economies. The coordinated pause signals that central banks view inflation risks as outweighing economic slowdown concerns, with tight labor markets and geopolitical tensions reinforcing the case for caution on rate cuts.

Source documents

Via News is a conduit. We point to the source documents behind this report — we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score4 source documents4 with a live linkVerifiability: Strong
  1. [1]News articleYahoo Finance· January 28, 2026
    The Fed might not cut interest rates for a while. Here are 5 things we’re watching.
  2. [2]News articleYahoo Finance· March 7, 2026
    US Inflation Gauges Likely Diverged Before War in Iran
  3. [3]Press releaseGlobeNewswire· February 5, 2026
    Årsregnskabsmeddelelse 2025
  4. [4]News articleNasdaq· November 21, 2025
    Stocks Rally as Chip Makers Rebound

In this story · Knowledge Files

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,577 source documents archived
Query this data → isubstrate.com